Cargando…
Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
BACKGROUND: Anaplastic lymphoma kinase (ALK) fusion is an important oncogenic driver in non-small cell lung cancer (NSCLC). Reports on the intergenic region (IGR) as an ALK fusion partner are rare. Here, we report the case of a patient with advanced NSCLC harboring a human immunodeficiency virus typ...
Autores principales: | Gu, Xiaodong, Wang, Wenxian, Wu, Wei, Zhang, Yiping, Shao, Lan, Santarpia, Mariacarmela, Christopoulos, Petros, Myall, Nathaniel J., Shi, Zhiyong, Lou, Guangyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186176/ https://www.ncbi.nlm.nih.gov/pubmed/35693284 http://dx.doi.org/10.21037/tlcr-22-288 |
Ejemplares similares
-
High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
por: Li, Yan, et al.
Publicado: (2022) -
Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report
por: Zeng, Zhen, et al.
Publicado: (2022) -
Metastatic pulmonary carcinoids with EML4-ALK fusion response to ALK inhibitors: two case reports and review of literature
por: Lei, Xi, et al.
Publicado: (2022) -
Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report
por: Zhai, Xiaoqian, et al.
Publicado: (2022) -
Rectal gastrointestinal stromal tumor with metachronous liver metastasis demonstrated no relapse after multidisciplinary team discussion and comprehensive treatment: a case report
por: Zhang, Xuan, et al.
Publicado: (2022)